Press Releases

Date	Title and Summary	Additional Formats
Toggle SummaryFeb032016	Fate Therapeutics to Present at Leerink Partners 5th Annual Global Healthcare Conference SAN DIEGO, Feb. 03, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapeutics for cancer and immune disorders, announced today that Scott Wolchko, President and Chief Executive Officer, will be Read All »	View HTML Fate Therapeutics to Present at Leerink Partners 5th Annual Global Healthcare Conference 10.8 KB
Toggle SummaryJan262016	Fate Therapeutics Announces FDA Clearance of Investigational New Drug Application for ProTmune for Prevention of Acute GvHD and CMV Infection Multi-Center, Randomized, Controlled Phase 1/2 Clinical Trial in Mobilized Peripheral Blood HCT to be Initiated in Mid-2016 Read All »	View HTML Fate Therapeutics Announces FDA Clearance of Investigational New Drug Application for ProTmune for Prevention of Acute GvHD and CMV Infection 16.8 KB
Toggle SummaryJan062016	Fate Therapeutics to Present at Biotech Showcase 2016 SAN DIEGO, Jan. 06, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapeutics for the treatment of cancer and immune disorders, announced today that Scott Wolchko, President and Chief Executive Read All »	View HTML Fate Therapeutics to Present at Biotech Showcase 2016 10.8 KB
Toggle SummaryDec072015	Fate Therapeutics Provides Update on Adoptive Immunotherapy Programs for Hematopoietic Cell Transplantation Supportive Interim Data from ProHema® PUMA Study Demonstrate the Therapeutic Potential of Programmed Donor Cells Clinical Development Strategy to Focus on Prevention of Life-Threatening Complications in Mobilized Peripheral Blood HCT ProTmune™ to Advance into Phase 1/2 Clinical Trial for Read All »	View HTML Fate Therapeutics Provides Update on Adoptive Immunotherapy Programs for Hematopoietic Cell Transplantation 27.5 KB
Toggle SummaryDec032015	Fate Therapeutics to Present at Oppenheimer & Co. 26th Annual Healthcare Conference SAN DIEGO , Dec. 3, 2015 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapeutics for the treatment of cancer and immune disorders, announced today that Scott Wolchko , President and Chief Executive Read All »	View HTML Fate Therapeutics to Present at Oppenheimer & Co. 26th Annual Healthcare Conference 16.6 KB
Toggle SummaryNov052015	Fate Therapeutics to Present Strategy for the Development of Off-the-Shelf Cancer Immunotherapies at ASH 2015 Proprietary Pluripotent Cell Platform for Engineered Adoptive Immunotherapies to be Highlighted During Two Poster Sessions Read All »	View HTML Fate Therapeutics to Present Strategy for the Development of Off-the-Shelf Cancer Immunotherapies at ASH 2015 61.9 KB
Toggle SummaryNov052015	Fate Therapeutics to Present Preclinical Data for ProTmune(TM) at ASH 2015 Annual Meeting First-in-Human Clinical Trial to Prevent Acute Graft-versus-Host Disease and Severe Infections Planned for 2016 Poster Presentations to Highlight Preclinical Findings and Potential Therapeutic and Pharmacoeconomic Value Propositions in HCT SAN DIEGO, Nov. Read All »	View HTML Fate Therapeutics to Present Preclinical Data for ProTmune(TM) at ASH 2015 Annual Meeting 61.9 KB
Toggle SummaryNov032015	Fate Therapeutics Reports Third Quarter 2015 Financial Results Pluripotent Cell Platform for Generating Off-the-Shelf Cancer Immunotherapies to be Presented at ASH 2015 Annual Meeting First-in-Human Clinical Trial of PROTMUNE™ to Prevent Acute GvHD and Severe Infections Planned for 2016 Reached 70% of Target Enrollment for PROHEMA® PUMA Study SAN Read All »	View HTML Fate Therapeutics Reports Third Quarter 2015 Financial Results 27.9 KB
Toggle SummaryOct292015	Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2015 Financial Results on November 3, 2015 SAN DIEGO, Oct. 29, 2015 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapeutics for the treatment of cancer and immune disorders, today announced that the Company will host a conference call and Read All »	View HTML Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2015 Financial Results on November 3, 2015 10.9 KB
Toggle SummaryOct282015	Fate Therapeutics Strengthens Intellectual Property Position With New U.S. Patent Covering Induced Pluripotent Cell Compositions Proprietary Pluripotent Cell Platform Has Broad Applicability for Development of Off-the-Shelf Cancer Immunotherapies Read All »	View HTML Fate Therapeutics Strengthens Intellectual Property Position With New U.S. Patent Covering Induced Pluripotent Cell Compositions 20.8 KB

DISCLOSURE NOTICE: The information contained in each press release is as of the date of the respective press release. The Company assumes no obligation to update any information or forward-looking statement contained in any press release as a result of new information or events or developments arising after the date of such press release.